SCHEMBL25613056

SCHEMBL25613056

CN(C)CCOc1nc2[nH]ccc2cc1C(C)(C)C

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 4/20 0.39
▸ ALDH1A1 P00352 1/20 0.39
▸ GAA P10253 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ NR4A2 P43354 3/20 0.36
▸ FEN1 P39748 1/20 0.35
▸ ABCB11 O95342 1/20 0.35
▸ LMNA P02545 1/20 0.35
▸ CYP1A2 P05177 1/20 0.35
▸ CYP2D6 P10635 1/20 0.35
▸ SCN1A P35498 1/20 0.35
▸ SCN2A Q99250 1/20 0.35
▸ TDP1 Q9NUW8 1/20 0.35
▸ SCN3A Q9NY46 1/20 0.35
▸ CHRNB2 P17787 1/20 0.35
▸ CHRNA4 P43681 1/20 0.35
▸ HTR7 P34969 1/20 0.34
▸ FGFR1 P11362 1/20 0.33
▸ KDR P35968 1/20 0.33
▸ ROCK2 O75116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25613335 0.84 FEN1 (0.39) FEN1FGFR1KDR
SCHEMBL25613045 0.84 ULK1 (0.39) MAPK1FEN1LMNAFGFR1KDR
SCHEMBL25613050 0.84 FEN1 (0.39) GAAMAPK1FEN1FGFR1KDR
SCHEMBL25613057 0.83 KDM4E (0.39) KDM4EALDH1A1GAAFEN1LMNA
SCHEMBL24005746 0.82 HTR7 (0.39) KDM4ENR4A2ABCB11LMNACYP1A2
SCHEMBL25613037 0.82 FEN1 (0.39) FEN1FGFR1KDR
SCHEMBL25613043 0.78 CDK1 (0.39) FEN1LMNAFGFR1KDR
SCHEMBL25613035 0.78 ULK1 (0.39) ALDH1A1FEN1LMNACYP1A2TDP1
SCHEMBL25613054 0.78 LTA4H (0.45) KDM4EALDH1A1CYP1A2CYP2D6
SCHEMBL25613169 0.77 BRD4 (0.40) MAPK1FEN1FGFR1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS FOCHON BIOSCIENCES, LTD. (CN) 2023-05-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230159527-A1 COMPOUNDS AS BCL-2 INHIBITORS BCL2, BCL2L2, BCL2L1 KDM4E 2788/4885ALDH1A1 3019/4885GAA 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback